Intensified Doxorubicin-Based Regimen Efficacy in Residual Non-Hodgkin's Lymphoma Disease: Towards a Computationally Supported Treatment Improvement
From MaRDI portal
Publication:2788513
DOI10.1051/mmnp:2007003zbMath1337.92111OpenAlexW2118773579MaRDI QIDQ2788513
K. Marron, Noël Dahan, Zvia Agur, Vladimir Vainstein, Yuri Kogan, Benjamin Ribba
Publication date: 19 February 2016
Published in: Mathematical Modelling of Natural Phenomena (Search for Journal in Brave)
Full work available at URL: https://doi.org/10.1051/mmnp:2007003
heterogeneitymathematical modelchemotherapyavascular tumourdoxorubicinhybrid cellular automataCHOPnon-Hodgkin lymphomavascular tumour
PDEs in connection with biology, chemistry and other natural sciences (35Q92) Medical applications (general) (92C50)
Related Items
Cites Work
- Unnamed Item
- Unnamed Item
- A mathematical model of Doxorubicin treatment efficacy for non-Hodgkin's lymphoma: investigation of the current protocol through theoretical modelling results
- Reduction of cytotoxicity to normal tissues by new regimens of cell-cycle phase-specific drugs
- A theoretical analysis of interval drug dosing for cell-cycle-phase- specific drugs
- Hopf point analysis for angiogenesis models
- Growth of necrotic tumors in the presence and absence of inhibitors
- Growth of nonnecrotic tumors in the presence and absence of inhibitors
- A mathematical model of vascular tumour growth and invasion
- Improving Cancer Therapy by Doxorubicin and Granulocyte Colony-Stimulating Factor: Insights from a Computerized Model of Human Granulopoiesis